UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000015971 |
|---|---|
| Receipt number | R000018577 |
| Scientific Title | A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer. |
| Date of disclosure of the study information | 2015/01/01 |
| Last modified on | 2019/12/20 18:51:05 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2014/12/16 19:30:03 | ||
| 2 | Update | 2015/02/03 17:53:00 | Recruitment status |
|
| 3 | Update | 2016/03/23 19:11:08 | Recruitment status Last follow-up date |
|
| 4 | Update | 2016/03/23 19:48:24 | Organization Organization Division name Organization Institute Organization Organization1 |
|
| 5 | Update | 2017/04/05 16:51:07 | Target sample size |
|
| 6 | Update | 2017/04/05 17:19:42 | Target sample size |
|
| 7 | Update | 2018/06/19 15:45:40 | Name of primary person or sponsor Organization Name of secondary funder(s) Institutions |
|
| 8 | Update | 2018/12/18 19:42:29 | Publication of results URL related to results and publications |
|
| 9 | Update | 2019/12/20 18:51:05 | Number of participants that the trial has enrolled Date of the first journal publication of results |
